DermTech is a molecular diagnostic company developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Co.'s focus is skin cancer. Co. provides the DermTech Melanoma Test for the early detection of melanoma and is developing a product for non-melanoma skin cancer. Co. is also working on products to assess precancerous genomic changes associated with sun UV exposure to the skin. Co. has additional skin cancer product offerings, including for non-melanoma skin cancers (basal cell and squamous cell cancers), under development. We show 13 historical shares outstanding datapoints in our DMTK shares outstanding history coverage, used to compute DMTK market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DMTK market cap history over the course of time is important for investors
interested in comparing DMTK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DMTK versus a peer is one thing; comparing
DMTK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DMTK can fluctuate over the course of history.
With this page we aim to empower investors researching DMTK by allowing them to research the DMTK market cap history. |
Free DMTK Email Alerts:
Video: The Importance of Market Cap
